Telix Pharmaceuticals Limited’s Post

I get asked a lot about why manufacturing and supply chain is so important in radiopharma R&D and commercialization. This short video gives a good overview of the “why?”: - Faster R&D - Specialized, IP-rich capabilities (ie alpha, bioconjugatjon) - Better quality control - Supports and “backs up” key commercial manufacturing and distribution partnerships in major markets - Certainty of patient access, every day The needs of radiopharma tomorrow are unique and we are working - with key partners - to deliver those future capabilities to better serve patients with unmet medical need. #SeeItTreatIt

Very pleased to share this short video on TMS; explaining how Telix continues to invest in manufacturing and supply chain - a critical area for successful radiopharmaceutical development. These facilities also help boost our ability to develop novel agents and get them into the clinic.

On Wednesday, April 24th, the final discussion for one of the largest Kansen voor West II projects took place: FIELD-LAB. Representing Kansen voor West, Jeroen Elzenaar, Ruud van Raak en Tessa de Boer visited Petten to meet with Karlijn van der Schilden, Paula van der Vlies, Angelique de Boer-l'Istelle en Vinod Ramnandanlal. The Kansen voor West II project, named “Advancing Nuclear Medicine, Petten FIELD-LAB,” has resulted in a state-of-the-art GMP production facility. FIELD-LAB contributes to the acceleration of the development of new nuclear medicines. This facility is utilised for the production of promising radioactive materials for the preparation of innovative nuclear medications. FIELD-LAB also ensures the development of the necessary production processes. Significant achievements so far include a sustainable concept of a production system for two promising so-called starting materials and base material for two new therapies for cancer treatment. A tracer is being developed to better select patients for chemotherapy. Additionally, a dozen feasibility studies have been initiated for the product development of industrial parties. #precisionmedicine #healthcareinnovation #medicine #innovation

The European Association of Nuclear Medicine (EANM) and Nuclear Medicine Europe (NMEU) express disappointment over the recent European Parliament vote on the #Pharmaceutical #Regulation and Directive, which did not incorporate their proposed amendments aimed at updating the regulatory framework for #radiopharmaceuticals. Despite the pivotal role #NuclearMedicine plays in modern healthcare, especially in cancer care as recognized by EU initiatives like the SAMIRA Action Plan, the current legislative approach fails to acknowledge the significant advancements in radiopharmaceuticals since 2004. This oversight poses challenges to the industry and clinical sectors, leading to uncertainties and reduced availability of radiopharmaceuticals across Europe. EANM and Nuclear Medicine Europe advocate for a regulatory framework that aligns with the evolving landscape of Nuclear Medicine, emphasizing the need for updated definitions and provisions to support the growth and accessibility of radiopharmaceuticals. They call upon policymakers to reconsider these developments and ensure that the revised legislation reflects the advancements in Nuclear Medicine, ultimately benefiting patients across the EU. Download the full statement : https://lnkd.in/ewenrYx

PanMediso Spotlight｜Novartis Nuclear Medicine Revenue Exceeds $1 Billion in the First Three Quarters Novartis' third-quarter report reveals that global sales of the radioligand therapy Pluvicto reached $386 million, a 50% year-over-year increase, with year-to-date sales surpassing $1.04 billion, up 47%. Pluvicto is a radioligand therapy that combines a small molecule targeting PSMA (prostate-specific membrane antigen) with the radioactive isotope 177Lu. According to Novartis' financial report, the company has submitted a filing for Pluvicto's use in second-line treatment of PSMA-positive mCRPC. Once approved, this indication is expected to drive Pluvicto's sales to new heights for the year. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #Nucleardrugs #Novartis #Pluvicto #177Lu #PSMA

✨ An early christmas gift for IRE - Institute for radioelements with the arrival of a 30 MeV IBA cyclotron at its Fleurus site. Total investment: over 30 million euros, including five million for the cyclotron alone. This “strategic investment” marks a “decisive step in IRE's drive to expand its production capacity and strengthen its leadership in radiopharmaceutical production. Erich Kollegger, CEO of IRE, stated: "The arrival of the IBA cyclotron is a significant turning point in IRE's history. This project demonstrates our capacity to innovate, diversify our activities, and control the entire production chain of essential radionuclides for nuclear medicine. We are committed to meeting the growing market needs and maintaining our position as an industry leader." 👉 See full article (French): https://lnkd.in/e5nt9K_r 👉 See full release: https://lnkd.in/e-Ka5sUr

🔗PHSE joins Nuclear Medicine Europe, the Industrial Association representing the leading pharmaceutical and imaging equipment companies in the field of nuclear medicine throughout Europe. Today's handshake at #EANM2024 Congress between Martinus Blauwhoff, President of Nuclear Medicine Europe, and Paul Rice, Chief Development Officer of PHSE International, kicks off the valuable #partnership.   “We have identified the Nuclear Medicine Europe Association as an opportunity to engage with industry experts, ranging from pharmaceutical companies to reactor operators worldwide, which we see as an essential part of our continuous improvement in offering highly specialised global transport services for the radiopharmaceutical market. Our first-hand involvement in working groups on topics of mutual interest, ranging from #SecurityOfSupply, #Therapy, #Regulatory Affairs & Quality, and the #Transport, will hopefully help bring real value to the complex radiopharmaceutical supply chain. While in the past drug distribution was considered the last chain in the manufacturing process, we strongly believe that logistics is increasingly a key asset and critical success factor in meeting the association’s challenges of #Innovation, #HealthcareForEveryone and #PatientSafety within the sector. The three fundamental pillars that drive our daily actions as well”, said Paul Rice. #DeliveringRadiopharmaceuticals #NewPartnership #NuclearMedicineEurope #PHSE #EANM2024

📣 𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿 𝗥𝗮𝗶𝘀𝗲𝘀 𝗙𝗼𝗿𝗲𝗰𝗮𝘀𝘁 𝗳𝗼𝗿 𝟮𝟬𝟮𝟰! 📈 Based on our 𝘀𝘁𝗿𝗼𝗻𝗴 𝟵-𝗺𝗼𝗻𝘁𝗵 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 and 𝗽𝗼𝘀𝗶𝘁𝗶𝘃𝗲 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗼𝘂𝘁𝗹𝗼𝗼𝗸 for Q4, our Executive Board has 𝗿𝗮𝗶𝘀𝗲𝗱 𝘁𝗵𝗲 𝗮𝗻𝗻𝘂𝗮𝗹 𝗳𝗼𝗿𝗲𝗰𝗮𝘀𝘁 for 2024 🙌 ▶️ 𝗦𝗮𝗹𝗲𝘀: Now expected at ~𝗘𝗨𝗥 𝟮𝟵𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 (previously EUR 265 million) ▶️ 𝗘𝗕𝗜𝗧 𝗯𝗲𝗳𝗼𝗿𝗲 𝘀𝗽𝗲𝗰𝗶𝗮𝗹 𝗶𝘁𝗲𝗺𝘀: Now anticipated at ~𝗘𝗨𝗥 𝟲𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 (previously EUR 55 million) 𝗧𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 to our 𝘁𝗲𝗮𝗺𝘀, 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀, 𝗮𝗻𝗱 𝗰𝘂𝘀𝘁𝗼𝗺𝗲𝗿𝘀 who drive our success in 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗻𝘂𝗰𝗹𝗲𝗮𝗿 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 and radiopharmaceutical innovation. Together, we're building the 𝗳𝘂𝘁𝘂𝗿𝗲 for patients and medical professionals worldwide. 💙 #Investors #FY2024  #NuclearMedicine #Radiopharmaceuticals #ContributingToSavingLives  

What if hospitals could no longer receive radiopharmaceuticals due to new legislation banning a key material in their transport containers? During the recent congress, our interactions with industry partners revealed a relative absence of awareness about the European Chemicals Agency’s (ECHA) 11th recommendation to include lead metal in the REACH Authorization List. This recommendation proposes banning the use of lead in various applications, including the transport of #radiopharmaceuticals. If enacted, this regulation could have dramatic repercussions for the #nuclearmedicine community and, consequently, for patients. Initially discussed at a networking event in May 2023, the Nuclear Medicine Europe Transport Experts Working Group subsequently published a "Position Paper on the Ban on Lead for the Transport of Radiopharmaceuticals." This document highlights the potential challenges and consequences of the regulation, while also outlining considerations for a transition that balances environmental objectives with the practical needs of healthcare providers and patients. Today, we issued an official statement in response to the European Commission, which has decided not to pursue a ban on lead. This outcome reflects a significant collective effort from Working Group members and our advocacy for nuclear medicine among legislators, who are now better informed about the implications of legislation that could restrict patient access to essential care. Naturally, Nuclear Medicine Europe and the Transport Experts Working Group fully support the continued development and adoption of alternative materials to lead wherever feasible. For more details, please read our full statement in the news section : https://lnkd.in/dxsmMqiv To know more about the Transport Experts Working Group : https://lnkd.in/dMPDVSw9

It feels like the Christmas season has arrived a little early at Telix Manufacturing Solutions in Brussels South, where two new cyclotrons have been installed. These cyclotrons, supplied by GE HealthCare and IBA, strengthens Telix's position as a major nuclear medicine production facility, serving as the Company’s primary manufacturing site for radioisotopes and patient doses across the EMEA region and beyond. Darren Patti, Group Chief Operating Officer, Telix Pharmaceuticals Limited said, “This year, more than 10 million radiopharmaceutical procedures will be performed in the EU. These new cyclotrons, manufactured by the world leaders in particle accelerator technology, will deliver significant flexibility and reliable supply from Telix’s first bench-to-bedside manufacturing facility, to help meet this growing demand." 👉 Read the full release: https://lnkd.in/e9Wb-2mh